Tag
Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences Novartis will pay UK biotech Relation Therapeutics as much as US$1.7 billion to help…
Third-quarter operating income, adjusted for special items, rose to US$5.46 billion Swiss drugmaker Novartis, on a deal-making spree this year, reported a gain in operating income of 6 per…
Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, according to the Swiss drugmaker. Novartis will pay US$72 a share in cash,…
Novartis agreed to buy Tourmaline Bio in a deal valued at about US$1.4 billion as the Swiss drugmaker continues to pursue bolt-on deals to boost its drug pipeline. The Swiss drugmaker will…
